Melbourne manufactures oncolytic, anti-infective, liposomal, and other drug products. This site can produce around 15 million units annually, supporting global markets. Clinical and commercial supply for injectable high-potent cytotoxic and potent compounds as well as complementary sterile therapeutics, Complex high-potent liposomal/nanoparticle formulations. Drug product expertise include small volume sterile injectable production, lyophilization. Packaging services include state-of-the-art multipack line, vial containment technology and serialization.